AstraZeneca Reiterates Importance Of Salick To Developing Oncology
Executive Summary
AstraZeneca continues to see long-term value in Salick Health Care from the contact that the treatment clinics provide with current trends in oncology, AstraZeneca CEO Tom McKillop, PhD, said at a 1999 earnings review Feb. 24 in London.
You may also be interested in...
Bristol Exiting Oncology Distribution Business Ahead Of Part B Pinch
Bristol-Myers Squibb has signed an agreement to sell its Oncology Therapeutics Network unit prior to the 2005 reimbursement changes for chemotherapy drugs under the Medicare Rx law
Bristol Exiting Oncology Distribution Business Ahead Of Part B Pinch
Bristol-Myers Squibb has signed an agreement to sell its Oncology Therapeutics Network unit prior to the 2005 reimbursement changes for chemotherapy drugs under the Medicare Rx law
Seroquel, Atacand Lead AstraZeneca New Products; Prilosec Nears $6 Bil.
The anti-psychotic Seroquel is one of the fastest growing products in the AstraZeneca portfolio, with sales totaling $232 mil. in 1999, the company indicated at its 1999 operating results review Feb. 24 in London.